USF Health is providing COVID-19 vaccinations by invitation and appointment only to patients and employees who meet eligibility criteria defined by Florida Executive Order as supply of vaccine permits. Learn More.

Diabetes and Endocrinology Center

Request Appointment

(813) 396-2580

Refer a Patient

Diabetes Clinical Research: Finding a Cure

Image

Currently Enrolling T1D Studies

  • For individuals between the ages of 2.5-45 years with a first-degree relative (parent, child, sibling) with type 1 diabetes
  • For individuals between the ages of 2.5-20 years with a second-degree relative (grandparent, aunt, uncle, niece, nephew, cousin or half-sibling) with type 1 diabetes

Purpose: To identify individuals at-risk for T1D and offer close monitoring for disease progression as well as potential prevention study opportunities.

For more information visit TrialNet on the web. 

Study Cordinator:  Juanita O'Brian, NRCMA

Contact: usfdiabetesresearchc@usf.edu

  • For individuals > 6 years
  • Positive for two or more diabetes-related auto-antibodies
  • Normal Glucose Tolerance

Purpose:  To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Coordinator: Juanita O'Brian, NRCMA

Contact: usfdiabetesresearchc@usf.edu

  • For individuals > 3 years old
  • Positive for two or more diabetes-related auto-antibodies
  • Normal Glucose Tolerance

Purpose: To prevent or delay disease progression in Stage 1 Type 1 individuals (2 or more auto-antibodies and normal glucose tolerance).

Study Coordinator: Juanita O'Brian, NRCMA

Contact: usfdiabetesresearchc@usf.edu

 

  • For individuals > 12 years old
  • Diagnosed with Type 1 Diabetes within 150 days

Purpose: To preserve insulin production by preventing beta cell destruction in individuals newly diagnosed with T1D.

Study Coordinator: Ponja Hemphill, RN

Contact: usfdiabetesresearchc@usf.edu

  • For Individuals ages 8-17
  • Diagnosed with T1D within 42 days
  • Up to date on immunizations

Purpose: To determine whether an investigational drug called Teplizumab may help preserve insulin production in children and adolescents who were recently diagnosed with Type 1 Diabetes

Study Coordinator: Ponja Hemphill, RN

Contact: usfdiabetesresearchc@usf.edu

  • For individuals ages 2-17
  • Diagnosed with type 1 diabetes or insulin-requiring type 2 diabetes
  • Has NOT used a Continuous Glucose Monitoring device (CGM) in the last year

Purpose: To evaluate the safety of non-adjunctive CGM use in CGM naive participants, by assessing the number of hypoglycemic and diabetic ketoacidosis (DKA) events with use of CGM 

Study Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/BASIC

Contact: usfdiabetesresearchc@usf.edu

Currently Enrolling T2D Studies

  • For individuals ages 10-17
  • Diagnosed with type 2 diabetes for at least 12 weeks
  • Additional eligibility criteria will be reviewed with you by the study coordinator

Purpose: To test the safety and effectiveness of Linagliptin in combination with Empagliflozin (FDA approved for treatment of type 2 adults) in pediatric type 2 patients.

Study Coordinator: Janet Rodriguez, BSN, RN, CDCES, CRA-USF/BASIC

Contact: usfdiabetesresearchc@usf.edu

USF Diabetes Center Focuses on Pathway to Prevention

How Can I Help Find A Way to Prevent Type 1 Diabetes?